Conjunctival Lymphangiogenesis Was Associated with the Degree of Aggression in Substantial Recurrent Pterygia

Objective. To examine conjunctival lymphatic vessels and to analyze the relationship between lymphangiogenesis and aggressive recurrent pterygia. Methods. Tissues from 60 excised recurrent (including 19 of Grade 1, 28 of Grade 2, and 13 of Grade 3) pterygia were used in the study. Tissues from 9 nasal epibulbar conjunctivae segments were used as controls. Pterygium slices from each patient were immunostained with LYVE-1 monoclonal antibodies to identify lymphatic microvessels in order to calculate the lymphovascular area (LVA), the lymphatic microvessel density (LMD), and the lymphovascular luminal diameter (LVL). The relationship between lymphangiogenesis (LVA, LMD, and LVL) and pterygium aggression (width, extension, and area) was clarified. Results. Few LYVE-1 positive lymphatic vessels were found in the normal epibulbar conjunctiva segments. Lymphatic vessels were slightly increased in Grades 1 and 2 and were dramatically increased in Grade 3 recurrent pterygia. The LMD was correlated with the pterygium area in Grade 1 and 2 pterygia. In Grade 3, both LVA and LMD were significantly correlated with the pterygium area. Conclusions. Lymphangiogenesis was associated with the degree of aggression in recurrent pterygia, particularly in substantial Grade 3 recurrent pterygia.

[1]  Suk-Kyeong Lee,et al.  Inhibition of Lymphangiogenesis and Hemangiogenesis in Corneal Inflammation by Subconjunctival Prox1 siRNA Injection in Rats. , 2015, Investigative ophthalmology & visual science.

[2]  M. Jiménez-Martínez,et al.  Triple subconjunctival bevacizumab injection for early corneal recurrent pterygium: one-year follow-up. , 2015, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[3]  R. D. Stulting,et al.  Cosmetic regional conjunctivectomy with postoperative mitomycin C application with or without bevacizumab injection. , 2013, American journal of ophthalmology.

[4]  A. Demirok,et al.  Topical Application of Bevacizumab as an Adjunct to Recurrent Pterygium Surgery , 2013, Cornea.

[5]  G. E. Mirza,et al.  Overexpression of vascular endothelial growth factor receptor 2 in pterygia may have a predictive value for a higher postoperative recurrence rate , 2013, British Journal of Ophthalmology.

[6]  Yizhi Liu,et al.  Lymphatic microvessel density as a predictive marker for the recurrence time of pterygium: A three-year follow-up study , 2013, Molecular vision.

[7]  H. Lin,et al.  Comparative evaluation of lymphatic vessels in primary versus recurrent pterygium , 2012, Eye.

[8]  Haotian Lin,et al.  Increasing lymphatic microvessel density in primary pterygia. , 2012, Archives of ophthalmology.

[9]  W. Marsden.  I and J , 2012 .

[10]  D. Ribatti,et al.  Preliminary evidence of the presence of lymphatic vessels immunoreactive for D2-40 and Prox-1 in human pterygium. , 2011, Oncology reports.

[11]  I. Mohammed,et al.  Treatment of pterygium. , 2011, Annals of African medicine.

[12]  S. Kıvanç,et al.  The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery , 2011, Clinical ophthalmology.

[13]  Ş. Crăiţoiu,et al.  Angiogenesis in the pathogenesis of pterygium. , 2011, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[14]  K. Maruyama,et al.  Lymphangiogenesis and angiogenesis: concurrence and/or dependence? Studies in inbred mouse strains , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  Can Liu,et al.  Corneal lymphangiogenesis correlates closely with hemangiogenesis after keratoplasty. , 2010, International journal of ophthalmology.

[16]  S. Wiegand,et al.  Cutting Edge: Lymphatic Vessels, Not Blood Vessels, Primarily Mediate Immune Rejections After Transplantation , 2009, The Journal of Immunology.

[17]  Shiqi Ling,et al.  Crucial role of corneal lymphangiogenesis for allograft rejection in alkali‐burned cornea bed , 2009, Clinical & experimental ophthalmology.

[18]  F. Grehn,et al.  Antiangiogene Therapie bei Pterygiumrezidiven , 2009, Der Ophthalmologe.

[19]  Marcela F Eugarrios,et al.  Topical cyclosporin A and mitomycin C injection as adjunctive therapy for prevention of primary pterygium recurrence. , 2009, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[20]  R. Dana,et al.  Corneal Lymphangiogenesis: Implications in Immunity , 2009, Seminars in ophthalmology.

[21]  G. Geerling,et al.  [Antiangiogenic therapy for pterygium recurrence]. , 2009, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[22]  G. Ergun,et al.  Topical Cyclosporine A in the Prevention of Pterygium Recurrence , 2008, Ophthalmologica.

[23]  Terry Kim,et al.  The presence of T-lymphocyte subpopulations (CD4 and CD8) in pterygia: Evaluation of the inflammatory response , 2008, Advances in therapy.

[24]  R. Zimmerman,et al.  Lymphangiogenesis concurrent with haemangiogenesis in the human cornea , 2007, Clinical & experimental ophthalmology.

[25]  K. Maruyama,et al.  Time Course of Angiogenesis and Lymphangiogenesis After Brief Corneal Inflammation , 2006, Cornea.

[26]  P. Heikkilä,et al.  High LYVE-1–Positive Lymphatic Vessel Numbers Are Associated with Poor Outcome in Breast Cancer , 2004, Clinical Cancer Research.

[27]  D. Jackson.  Biology of the lymphatic marker LYVE‐1 and applications in research into lymphatic trafficking and lymphangiogenesis , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[28]  M. Orhan,et al.  The roles of T-lymphocyte subpopulations (CD4 and CD8), intercellular adhesion molecule-1 (ICAM-1), HLA-DR receptor, and mast cells in etiopathogenesis of pterygium , 2003, Ocular immunology and inflammation.

[29]  K. Alitalo,et al.  Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. , 2002, Investigative ophthalmology & visual science.

[30]  D. Jackson,et al.  LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan , 1999, The Journal of cell biology.

[31]  E. Tsironi,et al.  HLA-DR antigen expression in pterygium epithelial cells and lymphocyte subpopulations: an immunohistochemistry study. , 1995, German journal of ophthalmology.

[32]  P. Zlatar,et al.  [Surgical management of pterygium]. , 1969, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.